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Postrenal transplant erythrocytosis: A review of 53 patients. Review of
a large renal transplant experience revealed a 17.3% incidence of post-
transplant erythrocytosis. The influence of kidney source, pretrans-
plant hematocrit, duration of pretransplant dialysis, renal transplant
function, acute rejection, transplant renal artery stenosis, urinary tract
obstruction, smoking, diabetes, retention of native kidneys, splenecto-
my, parathyroidectomy, immunosuppression, hypertension, and liver
enzyme abnormalities on the development of erythrocytosis in 53
recipients was determined. Comparison was made with 49 control
recipients matched for kidney function, time after grafting, age, and
sex. Erythrocytosis occurred 3 to 90 months after transplantation and
persisted for 1 to over 84 months. Risk factors for the development of
erythrocytosis were smoking, diabetes, and a rejection free course. In
contradistinction to previous smaller series, erythrocytosis occurred in
patients with good renal function (serum creatinine 1.62 0.43 mg/dl)
without prominence of graft rejection, transplant artery stenosis or
obstruction. Despite therapeutic phlebotomy, 11 thromboembolic
events occurred in 10 of the 53 patients with erythrocytosis, but in none
of the controls (P < 0.001). The high incidence of erythrocytosis
following renal transplantation and the risk of associated thromboem-
bolic events should encourage awareness and controlled evaluation of
therapeutic modalities.
Erythrocytose post-transplantation rénale: Revue de 53 malades. La
revue d'une grande série de transplantations rénales a révdld une
incidence de 17,3% d'erythrocytoses post-transplantation. L'influence
de l'origine du rein, de l'hématocrite prétranspiantation, de Ia durée en
dialyse avant transplantation, de Ia fonction rénale du greffon, du rejet
aigu, d'une sténose de l'artère rénale du transplant, de I'obstruction
urinaire, du tabac, du diabète, de la conservation des reins propres, de
Ia splCnectomie, de Ia parathyroIdectomie, de l'immunosuppresion, de
l'hypertension, et des anomalies des enzymes hepatiques sur Ic déve-
loppement de l'érythrocytose chez 53 receveurs a etC déterminée. La
comparaison a été faite avec 49 receveurs contrôles, identiques pour
leur fonction rdnale, leur durée depuis Ia greffe, l'age, et le sexe.
L'erythrocytose est survenue 3 a 90 mois après transplantation et a
persisté de I a 84 mois. Les facteurs de risque de développement de
l'erythrocytose étaient Ic tabac, Ic diabCte, et l'absence de rejet. En
contradiction avec des etudes antérieures plus petites, l'Crythrocytose
est survenue chez des malades avec une bonne fonction rénale (créatin-
inémie 1,62 0,43 mg/dl) sans predominance de rejet du greffon, de
stCnose de l'artère du transplant, ni d'obstruction. Malgré des phléboto-
mies therapeutiques, 11 accidents thrombo-emboliques sont survenus
chez 10 des 53 malades avec une Crythrocytose mais chez aucun des
contrOles (P < 0,001). L'incidence élevée de l'erythrocytose après
transplantation rénale et le risque de complications thrombo-emboli-
ques associées devraient en encourager Ia misc en evidence, et l'évalua-
tion contrôlCe des modalités thérapeutiques.
elevation of erythropoietin production has been noted by sever-
al authors [1, 2, 4, 5, 6, 8, 9, 101, the etiology of post-transplant
erythrocytosis remains speculative. Acute or chronic allograft
rejection [4, 5, 8, 91 and transplant renal artery stenosis [1, 71
are the most frequently suggested etiologic factors. Erythropoi-
etin production by native kidneys [2] has also been implicated.
Other mechanisms which have been proposed on theoretical
grounds include: hydronephrosis [Ill, hepatic erythropoietin
production [12, 13], androgenic steroids, resetting of the thresh-
old for erythropoietin stimulation due to prolonged pretrans-
plant anemia, and resolution of hyperparathyroidism with its
associated marrow fibrosis [141.
A review of all patients followed at the Oregon Health
Sciences University (OHSU) Renal Transplant Clinic between
1975 and 1981 has revealed 53 patients with post-transplant
erythrocytosis (a period during which 319 patients underwent
transplantation). An extensive chart analysis of the patients
with erythrocytosis and a control population matched for age,
sex, and graft function was conducted to define the clinical
characteristics and evaluate possible etiologic factors leading to
post-transplant erythrocytosis.
Methods
Erythrocytosis was defined as a hematocrit of greater than or
equal to 51%. This value is greater than 2.5 SD above the OHSU
laboratory normal values (41.1 to 46.1 for males, 36.1 to 41.3 for
females) which are based on a Portland population of 300
healthy Red Cross blood donor volunteers. Red cell mass
studies, until recently, were not performed routinely.
All weekly transplant clinic laboratory data sheets from 1975
through 1981 were reviewed to define the population with
erythrocytosis. A total of 53 patients with erythrocytosis were
identified from among this group and included patients trans-
planted before 1975 and transferred from other centers. Trans-
plant clinic and hospital charts of each patient were reviewed to
assess clinical characteristics. To obtain an accurate erythrocy-
tosis incidence figure, 237 consecutive patients transplanted at
OHSU between September 1975 and September 1981 who
Erythrocytosis has been reported as an uncommon complica-
tion of renal transplantation [1—101. True erythrocytosis, with
an elevation of red blood cell mass and normal plasma volume,
has been documented in many, but not all, patients. Although
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Table 1. Clinical data of erythrocytosis patients
Abbreviations: Max Hct. maximum hematocrit: Tx. post-transplantation: Dur EC, duration in months with erythrocytosis; CHOB,
carboxyhemoglobin: SH, smoking history: RCM. red cell mass ( kg) NI d 28.3 4.1, NI 7 24.4 2.6; PV, plasma volume (/kg) NI d 33.5
5.2, NI 7 34.8 3.2; Surg proced, surgical procedures; Urol comp, urologic complications; RH, rejection history; Serum Cr, serum creatinine;
Throm events, thrombotic events.
Abbreviations under column headings are:
D, diabetic nephropathy: I interstitial disease; ON, glomerulonephritis: PCK, polycystic kidney disease; H, hereditary or congenital; S.
systemic disorder (see text): 0. obstructive uropathy; HY. hypertension.
Is, isolated high Hct.
S, smoker, X. ex-smoker, reformed prior to transplantation: N, never smoked.
N, bilateral nephrectomy: S. splenectom; P. parathyroidectomy.
Ob, ureteral obstruction: RAS, renal artery obstruction.
0. rejection free course; C, chronic rejection; A. history of acute reversible rejection(s).
P. phlebitis; CVA, cerebral event (stroke or transient ischemie attack); PE, pulmonary emboli.
I., alive with graft function: F. giaft failure; D, died with graft function.
retained a functional graft for at least 3 months were determined
to he in the at-risk patient population. (Three months was the
minimum post-transplant time prior to the onset of erythroeyto-
sis: therefore, only 237 of a total of 319 patients transplanted
during that period were at risk for developing crythrocytosis.)
Forty-one of the 53 patients with erythrocytosis were trans-
planted at Ol-ISU between 1975 and 1981.
To identify potential erythroeytosis risk factors, a control
population was selected to match the erythrocytosis population
for mean duration of follow-tip ssith a functional kidney trans-
plant (41.5 months). Because erythrocytosis developed at vari-
able times from the transplant date, the control gioup was
selected to have an equal period at risk for developing erythro-
cytosis. The selection process was as follows: All patients
followed at the OHSU renal transplant clinic during the same
time interval were arranged sequentially by duration of the
follow-up with functional graft. Fifty consecutive patients with
normal hematocrits (35 to 47%) were selected from the se-
quence to obtain a control population similar to the erythrocy-
tosis group for the duration of the follow-up. One patient who
did not meet the hematocrit requirement was excluded. Ihe
selection method resulted in a control group which was
matched with the erythrocytosis group not only for duration of
follow-up, but for age, sex, and graft function.
Patients were managed by a standard OHSIJ immunosup-
pression protocol utilizing maintenance azathioprine and pred-
nisone as well as a low-dose prednisone protocol for acute
rejection therapy. Anti-lymphocyte globulin was used 1977 to
1978 [15].
All data are expressed as the means SD and analyzed using
x2 or two-tailed Student's t tests. Significance is considered as
P < 0.05.
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Results
The incidence of erythrocytosis at the OHSU was 17.3% (41
of 237 consecutive patients with  3 month graft function). Its
onset was between 3 and 90 months post-transplant (mean = 17
months). The average maximum hematocrit (despite alteration
since 1979 by therapeutic phlebotomy for a hematocrit > 51%)
was 54.8 2.6% (range = 51 to 62%). Erythrocytosis occurred
in patients between 10 and 59 years of age (mean = 35.7
12.0). A single hematocrit value above 51 occurred as an
isolated finding in 13 patients, but those individuals had preced-
ing and subsequent determinations which were within 1 to 2%
of this arbitrary value. Erythrocytosis persisted for an average
of 20.1 months (range = 1 to 84 months) in the remaining 40
patients. No patients had coincidental thrombocytosis, leuko-
cytosis or splenomegaly, and no other causes of secondary
polycythemia were apparent clinically. Although arterial blood
gases, carboxyhemoglobin levels, and pulmonary function tests
were not available for all patients, significant pulmonary dis-
ease was not clinically apparent in any patient. Clinical features
are outlined in Table 1. The tabulated arterial blood gases
include those drawn specifically to evaluate erythrocytosis and
those representative of baseline pulmonary function (room air
gases without evidence of volume overload or pneumonia). The
red cell mass studies in most patients were not coincident with
the peak hematocrit but showed elevated red cell masses in four
out of seven patients studied. The other three patients had
GaisbOcks erythrocytosis.
Post-transplant erythrocytosis occurred in patients with ex-
cellent graft function and prognosis. Ninety-one percent (48 out
of 53) of the patients were alive with well preserved graft
function or had died with a functional kidney after a mean
follow-up of 41.5 months. The average serum creatinine at the
last follow-up in this group was 1.62 0.93 mg/dl. The control
and erythrocytosis groups were similar for average follow-up
time, graft function, and longevity (Table 2).
The groups were similar for mean age and sex. The pre-
transplant hematocrit, duration of pre-transplant dialysis and
number of pre-transplant transfusions were also similar (Table
3). The spectrum of underlying renal disease in patients with
erythrocytosis was qualitatively similar in the two populations
(Table 4). Diabetic nephropathy was over-represented in the
erythrocytosis group (P = 0.04). Hereditary or congenital
kidney diseases occurred more frequently in the control group
(P = 0.03). Polycystic kidney disease occurred with equal
frequency in both groups. Approximately 40% of each group
received living-related kidneys and 60% received cadaveric
grafts (Table 5). No apparent difference in the degree of donor-
recipient HLA mismatching was noted in the two groups. The
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Table 2. Graft function and prognosis
Average follow-up, months
Serum creatinine
Patients with functional graft
At last follow-up
Alive with functional graft
Died with functional graft
Patients returned to dialysis
Systemic disorders include amyloidosis, systemic lupus erythema-
tosis, and Henoch-Schdnlein purpura.
frequency of each HLA A and B antigen in the erythrocytosis
group was similar to 195 consecutive Oregon cadaver donors
and was not different from reported national data [16].
Erythrocytosis generally occurred in those with good kidney
function and without evidence of acute or chronic rejection.
Only five patients developed erythrocytosis during chronic
rejection and two patients during acute rejection superimposed
on chronic rejection (Table 6). Three times as many patients in
the erythrocytosis group had never experienced an acute rejec-
tion episode (P — 0.03). The percentage of each group with
clinically diagnosed chronic rejection and/or graft radiation
therapy was similar.
Living related
HLA-identical
Haplo-identical
Cadaveric
I antigen mismatch
2 antigen mismatch
3 antigen mismatch
4 antigen mismatch
Unknown mismatch
Table 5. Graft source
Control P value
21(39.6%) 20 (40%) NS
12 9 NS
NS
NS
NS
NS
NS
NS
NS
Other transplant complications potentially contributing to the
development of erythrocytosis are reviewed in Table 7. Al-
though partial ureteral obstruction was related temporally to an
elevated hematocrit in two patients, an equal number of control
patients suffered this complication. Renal artery stenosis and
hypertension requiring antihypertensives occurred equally in
both groups.
Table 8 reviews the prevalence of pretransplant spleneclomy.
nephrectomy, and parathyroidectomy in each population. Al-
though bilateral nephrectomies were more common in the
control population, this difference did not reach statistical
significance. The incidence of hypercalcemia and parathyroid-
ectomy was similar in both groups. Interestingly, two patients
underwent parathyroidectorny for the persistence of hyperpara-
thyroidism and hypercalcemia during sustained erythrocytosis
without influencing the hematocrit.
Prednisone and cytotoxic agents were not prerequisites for
Erythrocytosis Control P value
41.5 27.8 48.6 18.3 NS
1.62 0.93 1.67 0.67 NS
4853 (91%)
44 53(83%)
4/53 (8%)
5/53 (9.4%)
Erythrocytosis
47/49 (96%)
4749(96%)
049 (0%)
249 (4.1%)
NS
NS
P < 0.05
NS
Serum creatinine determined (mg dl sn) at last follow-up in
patients retaining functional transplant.
Table 3. Population characteristics
Erythrocytosis
9
32 (60.4%)
2
7
14
7
2
II
29 (59.2%)
5
3
10
0
53
34.4 12.0
29/24
Control P value
49
30.2 13.1 NS
2722 NS
Number
Age at transplant
Male/Female
Duration pretransplant
dialysis. months
Pretransplant hematocrit
Number of pretransplant
transfusions
0
I to 3
4 to 6
>6
NA'
9.1 9.2 11.5 18
23.7 4.7% 23.0 5.1%
Table 6. Rejection history
Erythrocytosis Control P value
Acute (reversible)
rejectionsa: 0
NA"
Chronic rejectionc
Radiation therapy
3 (57Y()
12 (22.6%)
9 (17.0%)
12 (22.6%)
17(32.1%)
NS
NS
NS
NS
NS
NS
NS
6(12.2%)
13(26.5%)
10 (20.4%)
12 (24.5%)
8(16.3%)
13 (24.5%) 4 (8.2%) 0.03
17 (32.1%) 18 (36.7%) NS
9 (17.0%) 11(22.4%) NS
8 (15.1%) 10(20.4%) NS
6 (11.3%) 6(12.2%) NS
7 (13.2%) 6(12.2%) NS
19 (35.8%) 19 (38.8%) NS
Number of patients in each population with respective number of
transfusions
Not available
'table 4. Renal disease
Erythrocytosis was related temporally to acute rejections in only
two patients, both with underlying chronic rejection.
NA—data not available.
Chronic rejection is defined as slowly increasing creatinine (without
other apparent etiologies) in the appropriate clinical setting.
Table 7. Transplant complications
Erythrocytosis Control
Glomerulonephriti s
Diabetic nephropathy
Polycystic kidney disease
Interstitial diseases
Hereditary or congenital
Systemic disorders
Obstructive uropathy
Hypertension
Unknown
IS (28.3%)
15 (28.3%)
3 (5.7%)
6(11.3%)
2 (3.8%)
3 (5.7%)
3 (5.7%)
2 (3.8%)
4 (7.5%)
20(40.8%)
6(12.2%)
2 (4.1%)
3 (6.1%)
8(16.3%)
I (2.0%)
3 (6.1%)
I (2.0%)
5 (lt).2%)
Erythrocytosis Control P value
Ureteral obstruction 2/53 (3.8%) 2/49 (4.1%) NS
P value Hypertension 35 53 (66%) 36/49 (73.5%) NS
Transplant renal
NS artery stenosis l/3" (1.9%) 2/49 (4.1%) NS
0.04
NS ' Hypertension defined here meant a blood pressure elevation signili
NS cant enough to require antihypertensive medications.
0.03 " Onset of hypertension and diagnosis of renal artery stenosis oc-
NS curred 2 years after the resolution of erythrocytosis.
NS
NS
NS
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Table 8. Surgical procedures in transplant recipientsa
Erythrocytosis Control P value
Splenectomy 12 (22.6%) 8 (16.3%) NS
Nephrectomy 10 (18.9%) 14 (28.6%) NS
Unilateral 3 (5.7%) 1 (2%) NS
Bilateral 7 (13.2%) 13(26.5%) NS (P = 0.09)
Parathyroidectomy 6b (11.3%) 6 (12.2%) NS
a This is the number of patients in each group that received surgical
procedure.
Two patients underwent parathyroidectomies during erythrocytosis
without influencing the hematocrit.
Erythrocytosis Control P value
Mild enzyme abnormalitya 22/53 (42%) 23/49 (46.9%) NS
Overt hepatitis" 4/53 (7.5%) 5/49 (10.2%) NS
a Any two of following: SGOT >40 U/liter (NI 9—37)
Alkaline phosphatase >120 U/liter (Ni 35—
105)
Lactic dehydrogenase >250 U/liter (Ni 135—
240)
Bilirubin >1.4 mg/dl (Nl 0.2—1.2)b Transaminases  3 x normal.
History of smoking
Smoker at last follow-up
Quit smoking prior to
transplant
No history of smoking
Erythrocytosis Control P value
31/53 (59.6%) 17/49 (34.7%) 0.02
21/53 (40.4%) 13/49 (26.5%) NS
10/53 (19.2%) 4/49 (8.2%) NS
22/53 (40.4%) 32/49 (65.3%) 0.02
the development of erythrocytosis (Table 9). One patient who
was not on prednisone or cytotoxic agents developed erythro-
cytosis. Another patient, treated with azathioprine but without
steroids, developed an elevated hematocrit. The average azathi-
oprine dose in the erythrocytosis group was identical to that of
the control group.
No specific medication could be linked to patients with
erythrocytosis. Diuretics were prescribed with equal frequency
in both groups.
Hepatic inflammation does not appear to contribute to post-
transplant erythrocytosis. A mild elevation of liver enzymes is
common following renal transplantation, but it occurred with
equal frequency in both groups (Table 10). Likewise, overt
hepatitis occurred equally in both populations.
A greater percentage of patients with erythrocytosis was
smokers compared to the control group (P = 0.02, Table 11).
Smoking, however, is not the only risk factor as over 40% of the
patients developing erythrocytosis had never smoked.
It is apparent that post-transplant erythrocytosis is not simply
a curious laboratory condition (Table 12). Approximately 10%
of patients with erythrocytosis had at least one episode of
phlebitis (complicated by pulmonary emboli in one patient).
Another 10% of patients suffered cerebrovascular accidents,
leading to death in one patient. No thromboembolic events
occurred in the control population (P <0.001). Figures 1, 2 and
3 demonstrate that thromboembolic events occur in patients
with varying severity, duration and time of onset of erythrocy-
tosis. Therapeutic phlebotomies to maintain the hematocrit to
less than 51% decreased the duration of severe erythrocytosis
and may have altered the natural spectrum of thrombotic
events.
Patients developing erythrocytosis were noted to have an
increased frequency of diabetes, history of smoking, and post-
transplant courses free from acute rejection. The lower frequen-
cy of bilateral nephrectomies in the erythrocytotic group ap-
proached but did not reach significance (P = 0.09). To evaluate
synergism between the four risk factors, all possible combina-
tions of the four variables were analyzed. The independence of
each of the clinical risk factors was subsequently evaluated by
fractionating the populations into patients with each single
variable in the absence of the second clinical feature of the
combination. x2 analysis was used to compare the erythrocyto-
sis and control groups. The three combinations which ap-
proached significance and their independent variables are dem-
onstrated in Table 13. It should be noted that none of the other
possible combinations nor any of the independently evaluated
parameters was significantly associated with erythrocytosis.
Discussion
Erythrocytosis is a common complication of renal transplan-
tation, occurring in over 17% of the OHSU population. The
time of onset was variable, occurring as early as 3 months or as
late as 7.5 years after transplantation. The elevated hematocrit
may be self-limited, but persistence for over 1 .5 years is not
uncommon. One patient has had erythrocytosis requiring inter-
mittent phlebotomies for 84 months. Although self-limited or
easily managed with phlebotomy, erythrocytosis can be associ-
ated with significant morbidity. Eleven thromboembolic events
occurred in 10 of the 53 patients. Other authors have confirmed
the high frequency and gravity of thromboembolic complica-
tions 1$, 9, 17]. Thrombotic events are not restricted to patients
with true erythrocytosis. Weinreb and Shih reported a 30%
incidence of thromboembolic complications in patients with
spurious (Gaisböcks) erythrocytosis unrelated to transplanta-
tion 118].
Furthermore, studies by Thomas et al in 1977 demonstrated
significant reduction in cerebral blood flow in 38 patients with
polycythemia defined as hematocrits of 47 to 53% [19]. These
findings and the rate of thrombotic complications led to the
establishment of aggressive therapeutic guidelines in 1979.
Since that time, therapeutic phlebotomies have been consistent-
ly performed when the hematocrit reaches 51%. The incidence
Table 10. Liver enzyme abnormalities
Table 9. Immunosuppression
Erythrocytosis Control P value
Average azathioprine,
mg/day SD 99.2 44.8 98.6 46.0 NS
No immunosuppression I patient 0 NS
No prednisone 2 patients 0 NS
No cytotoxic agents 1 patient 0 NS
Table 11. Smoking history
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Table 12. Complications of erythrocytosis
Erythrocytosis Control P value
Phlebitis 5/53 (9.4%) 0 0.03
Pulmonary emboli I 53 (1.9%) 0 NS
Cerebrovascular eventy 5/53 (9.4%) 0 0.03
All thromboembolic events 11/53 (20.8%) 0 < 0.001
The events include transient ischemic attacks (well documented) or
cerebrovascular accidents.
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of thrombotic events in patients with hematocrit of 51 to 54Y1
further supports aggressive therapy. Confirmation of the effica-
cy of this therapeutic approach would require controlled clinical
trials.
Several prior case reports link post-transplant erythrocytosis
to acute or chronic rejection [4. 5, 8, 9]. Abbrecht and Greene
[201 serially measured serum erythropoietin levels by bioassay
in seven patients before and after transplantation and noted
erythropoietin elevation during rejection episodes. Jepson et al
[4] evaluated post-transplant erythropoiesis in nine patients
developing erythrocytosis and nine controls. They also noted
elevated plasma and urinary erythropoietin levels in association
with graft rejection. Swales and Evans [81, however, noted that
only two out of seven patients with post-transplant erythrocyto-
sis had clinical evidence of rejection. He suggested that the
chief risk of erythrocytosis was thromboembolism, and that
accompanying rejection was subclinical with a good prognosis.
Erythrocytotic patients in our series had excellent allograft
function and prognosis. Allograft rejection did not seem to be a
major etiologic factor in post-transplant erythrocytosis. Trans-
plant renal artery stenosis with elevated erythropoietin levels
has been reported to cause erythrocytosis [1, 71. Allograft
artery stenosis, however, occurred with equal frequency in
both populations suggesting that it does not play a major
etiologic role. Ureteral obstruction, another possible precursor
of erythrocytosis [11], occurred in only a small percentage of
patients in this study. Hypertension, by virtue of increased
A 1-6 7-12 1324 25-36 37-48 >48
Isolated
Duration of erythrocytosis, months
Fig. 2. Patients by duration of ervthrocvtosis and thromboembolic-
events. Shaded area represents thromboembolic events in each
population.
3-6 7 12 1324 25-36 37-48 >48
Onset in months post-transplant
Fig. 3. Patients by tOne of onset of ervtliro tosi.s post-transplant and
thromboembolic event.s - Shaded area represents thromboembolic
events in each population.
plasma renin activity, small vessel disease in the allograft, or
because of an associated plasma volume contraction, theoreti-
cally could lead to erythrocytosis [21, 22]. Although hyperten-
sion is common post-transplant, it was no more common in
patients developing elevated hematocrit.
Erythropoietin production by native kidneys leading to eryth-
rocytosis has also been postulated. Dagher et al [21 selectively
catheterized veins of native and transplanted kidneys in three
patients and demonstrated elevated erythopoietin concentra-
tions from the native kidneys. An increased venous effluent
concentration of erythropoietin in the face of poor renal blood
flow accompanying endstage disease, however, is not indicative
of increased absolute production. Native kidneys arc not neces-
sary for the development of erythrocytosis as seven of 53
patients in our series had pretransplant bilateral nephrectomies.
Renal tissue is the major, but not the only, source of
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Table 13. Risk factor analysis
Variable Erythrocytosis Control P value
Diabetic smokers 8/53 (15.1%) 1/49 (2.0%) 0.02
Smokers (nondiabetic) 23/53 (43.4%) 16/49 (32.7%) 0.27
(Nonsmoking) diabetics 7/53 (13.2%) 5/49 (10.2%) 0.64
Smokers with native kidneys 25/53 (47.2%) 11/49 (22.4%) 0.01
Smokers with bilateral
nephrectomy 6/53 (11.3%) 6/49 (12.2%) 0.89
Nonsmokers with native
kidneys 21/53 (39.6%) 25/49 (51.0%) 0.25
Smokers without acute rejec-
tion 6/53 (11.3%) 1/49 (2.0%) 0.06
Smokers with acute rejec-
tion 25/53 (47.2%) 16/49 (32.7%) 0.14
Nonsmokers without acute
rejection 7/53 (13.2%) 3/49 (6.1%) 0.23
erythropoietin. The liver is able to secrete significant quantities
of erythropoietin [12, 13]. Furthermore, viral or drug-induced
hepatitis in uremic patients is accompanied frequently by a rise
in serum erythropoietin and improvement in anemia 13].
Although both hepatitis and mild liver enzyme abnormalities
are common after transplant, they did not appear to contribute
to post-transplant erythrocytosis.
The present series rules out a significant role of immunosup-
pression therapy, splenectomy, prolonged pretransplant anemia
with the resetting of the threshold level for erythropoietin
production, and the resolution of spontaneous or surgical
hyperparathyroidism.
Although the previously suggested causes of erythrocytosis
did not play significant roles in the present series, several other
risk factors were identified. A history of smoking, although not
a necessary feature, was the most significant factor. Other
positive correlates included diabetes, absence of acute rejection
episodes, and to a lesser extent, retention of native kidneys.
Interestingly, these clinical risk factors acted synergistically; no
single clinical risk factor was cofrelated significantly with
erythrocytosis. The small numbers of patients in the various
subgroups, however, may have prevented differences from
reaching statistical significance. The prominence of vascular
disease in both diabetic patients and smokers suggests that
renal vascular disease could play an etiologic role. The lack of
correlation with clinically apparent chronic rejection would
seem to refute a vascular hypothesis, although the superimposi-
tion of renal failure might negate a tendency toward
erythrocytosis.
One could speculate that altered erythropoietin homeostatic
mechanisms in the denervated transplant kidney superimposed
on a setting of multiple risk factors leads to post-transplant
erythrocytosis. Intrarenal prostaglandins, which stimulate
erythropoietin production after hypoxic, ischemic, and beta-2-
adrenergic stimuli, may play a regulatory role [23].
In summary, the clinical characteristics of 53 patients with
post-transplant erythrocytosis have been reviewed. Although
previously speculated etiologies play little or no role, several
risk factors were defined. The high frequency of this transplant
complication, the excellent allograft prognosis, and the frequen-
cy of associated thromoembolic events should encourage estab-
lishment of specific therapeutic guidelines. Further character-
ization of the disorder and the role of various therapeutic
modalities need evaluation by controlled clinical trials.
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